A newly published charter for the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) expands vaccine-safety monitoring as a primary function and reshapes membership criteria after a court ruling suspended parts of prior appointments. The changes align with Health and Human Services Secretary Robert Kennedy’s push to broaden attention to vaccine safety. The policy shift comes alongside separate reports of leadership delay in an MMWR COVID-vaccine effectiveness study, where concerns were raised about observational methodology used for vaccine effectiveness estimates. For biopharma, these updates matter because ACIP guidance and CDC publication timelines can affect how vaccine evidence is interpreted, communicated, and incorporated into future program design and stakeholder confidence.